In the present study, we aimed to test a novel immunotherapeutic approach’s ability to ameliorate tau-related pathology by blocking oligomer mediated toxicity, using an AD transgenic (Tg) model, which we developed (Boutajangout et al., 2008, 2009, 2010). The gene discussed is MAPT; the disease is Alzheimer disease.